Shield Therapeutics Edison

Shield Therapeutics


£65.6m market cap

55.8p last close

Shield Therapeutics is a commercial-stage pharmaceutical company. Its proprietary product, Feraccru, is approved by the EMA and FDA for the treatment of iron deficiency. Feraccru is marketed through partners Norgine, AOP Orphan and Ewopharma.

Investment summary

Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the UK. Its primary focus is the commercialisation of Feraccru/Accrufer, approved by the EMA and FDA for the treatment of iron deficiency in adults, with or without anaemia. The commercialisation of Feraccru in Europe, Australia and New Zealand is in the hands of distribution partner Norgine, and the product has been licensed to ASK Pharm in China. Shield is broadening its strategy for commercialisation in the US and will continue ongoing discussions with potential partners and in parallel explore the benefits of marketing Accrufer itself. At 30 November 2020 Shield had an unaudited cash balance of £3.8m, loan facility agreements totalling c £4.4m extend the runway to the end of 2021. Our forecasts are under review.

Y/E Dec
Revenue (£m)
PBT (£m)
EPS (p)
P/E (x)
P/CF (x)
2018A 11.9 (2.5) (5.2) (1.5) N/A N/A
2019A 0.7 (6.4) (9.1) (7.5) N/A N/A
2020E N/A N/A N/A N/A N/A N/A
2021E N/A N/A N/A N/A N/A N/A
Industry outlook

The market for iron deficiency is substantial and Feraccru is a unique oral formulation of iron developed to overcome the side-effect profile of salt-based oral iron therapies and provides an alternative treatment to intravenously administered iron.

Last updated on 14/01/2021
Register to receive research on Shield Therapeutics as it is published
Share price graph
Balance sheet
Forecast net debt (£m) N/A
Forecast gearing ratio (%) N/A
Price performance
Actual (12.8) (58.1) (68.1)
Relative* (16.5) (63.5) (64.9)
52-week high/low 172.5p/48.5p
*% relative to local index
Key management
Tim Watts CEO

Content on Shield Therapeutics